NCT01599104

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension

A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,161 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

This study assessed the efficacy of LCZ696 in Japanese patients with essential hypertension

Conditions

• Essential Hypertension

Interventions

Type	Name	Description
DRUG	LCZ696	200 mg (one tablet) or 400 mg (2 tablets of 200mg) once daily
DRUG	Olmesartan	Olmesartan 20 mg capsule one daily
DRUG	Placebo	Placebo to LCZ696 or Olmesartan

Timeline

• Start date: 2012-06-01
• Primary completion: 2013-04-01
• Completion: 2013-04-01
• First posted: 2012-05-15
• Last updated: 2015-10-16
• Results posted: 2015-08-06

Locations

61 sites across 1 country: Japan